The global drug discovery informatics Market was valued at US$ 3.39 billion in 2024 and is expected to reach US$ 8.17 billion by 2031. The Drug Discovery Informatics market size is estimated to register a CAGR of 13.7% during 2025-2031.

The global drug discovery informatics market is expected to grow significantly during the forecast period, driven by increasing R&D activities, demand for targeted therapies, and technological advancements in data analytics. Countries such as the United States, Germany, Japan, and China are leading this shift, propelled by the need for faster drug development, improved accuracy in drug screening, and reduced research costs. The integration of AI and machine learning into Drug Discovery Informatics platforms is enabling real-time analysis of biological and chemical data, enhancing decision-making and productivity across the drug discovery pipeline.

Pharmaceutical companies are leveraging drug discovery informatics for hit identification, lead optimization, and predictive modeling, which supports quicker identification of promising drug candidates. This is particularly important in therapeutic areas such as oncology, neurology, and infectious diseases, where time-to-market is critical. Advanced informatics tools are also supporting the growing trend of personalized medicine by facilitating genomic data analysis and biomarker discovery.

Additionally, the expansion of collaborative research models, strategic alliances between pharma and tech companies, and supportive government initiatives are accelerating market adoption. With rising healthcare demands, aging populations, and the push toward more efficient research processes, Drug Discovery Informatics is playing a central role in transforming drug development worldwide. Public-private partnerships and increased funding in biomedical innovation are also contributing to the robust growth of the Drug Discovery Informatics market.

Jubilant Pharma Limited., Certera., Thermo Fisher Scientific Inc., Dassault Systemes SE, Revvity Inc., Selvita., Eurofins Scientific SE., Collaborative Drug Discovery, Inc., and Charles River Laboratories International Inc are among the key global drug discovery informatics market players that are profiled in this market study.

The overall global drug discovery informatics market size has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the global drug discovery informatics market size. The process also helps obtain an overview and forecast of the market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain analytical insights. This process includes industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the global drug discovery informatics market.